[Correspondence] Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial

In prespecified analyses from the SELECT trial, semaglutide reduced major adverse cardiovascular events (MACE) compared with placebo, with only about one-third of benefit mediated by waist circumference change.1 John Deanfield and colleagues report multiple interesting findings in the placebo group.